Human neutralizing anti-tetanus toxin monoclonal antibody and its applications
US11725046B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Dec 28, 2018 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | May 15, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/33
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention describes fully native human neutralizing monoclonal antibodies against tetanus toxin. The invention developed fully native human neutralizing monoclonal antibodies against tetanus toxin through a systematic high through-put platform that is specialized for identifying and developing human native antibody. The neutralizing monoclonal antibodies described in the invention can be used in the prevention, treatment and detection of Clostridium tetani infection. The fully human neutralizing monoclonal antibodies developed in the invention have a high affinity toward tetanus toxin, as well as possessing high neutralizing activities against the toxin, safe of use with high disease prevention effectiveness, free of exogenous virus contamination, and are widely applicable to various human groups with strong industrial applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.